stalled to closed
Affinity® was proven to support healing in a prospective, multicenter, randomized controlled trial (RCT)1
- Assessed efficacy of Affinity vs standard of care (SOC)* in 76 patients with refractory diabetic foot ulcers (DFUs) (>4 weeks' duration)
- Digital planimetry† accurately captured DFU area, depth, and volume
- Affinity significantly improved the incidence and time to wound closure (both P<0.05)
Significantly more DFUs were closed with Affinity than SOC at 12 weeks and 16 weeks (P=0.04)1
Frequency of wound closure‡
*Debridement, infection elimination, dressings, and offloading by total contact casting. †Silhouette® laser-assisted wound measurement device. ‡Estimated frequency of wound closure at weeks 12 and 16; estimated from Cox adjusted survival data for wound closure.
Significantly more DFUs achieved >60% reduction in wound area (P=0.02) and depth (P=0.04) and >75% reduction in volume (P=0.06) with Affinity than SOC1
*Debridement, infection elimination, dressings, and offloading by total contact casting. †Silhouette® laser-assisted wound measurement device.
Median time to DFU closure with Affinity was 11 weeks. SOC failed to attain this endpoint at 16 weeks.1
In real-world patients, Affinity has been shown to reduce wound area and support closure in a wide variety of wounds from head to toe.2-4
at 3 weeks
at 6 weeks
at 9 weeks
- Serena TE, et al. J Comp Eff Res. 2019. doi:10.2217/cer-2019-0142
- Lambert et al. Presented at: Symposium on Advanced Wound Care Fall 2015; September 26-28, 2015; Las Vegas, NV.
- Sabo M, et al. Chronic Wound Care Manage Res. 2018;5:1-4.
- Carpenter et al. Presented at: 4th Annual Innovations in Wound Healing Conference; December 7-10, 2017; Bimini, Bahamas.